Several brokerages have updated their recommendations and price targets on shares of Teva Pharmaceutical Industries (NYSE: TEVA) in the last few weeks:

  • 9/12/2016 – Teva Pharmaceutical Industries was given a new $63.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 9/12/2016 – Teva Pharmaceutical Industries was given a new $69.00 price target on by analysts at Jefferies Group. They now have a “buy” rating on the stock.
  • 9/12/2016 – Teva Pharmaceutical Industries was given a new $66.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 9/11/2016 – Teva Pharmaceutical Industries was given a new $71.00 price target on by analysts at RBC Capital Markets. They now have a “buy” rating on the stock.
  • 9/9/2016 – Teva Pharmaceutical Industries was downgraded by analysts at TheStreet from a “buy” rating to a “hold” rating.
  • 9/2/2016 – Teva Pharmaceutical Industries was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $66.00 price target on the stock.
  • 8/31/2016 – Teva Pharmaceutical Industries was given a new $61.00 price target on by analysts at Leerink Swann. They now have an “outperform” rating on the stock.
  • 8/25/2016 – Teva Pharmaceutical Industries had its “neutral” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $51.63 price target on the stock, down previously from $59.00.
  • 8/25/2016 – Teva Pharmaceutical Industries had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $64.00 price target on the stock, down previously from $70.00.
  • 8/24/2016 – Teva Pharmaceutical Industries was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $58.99 price target on the stock.
  • 8/16/2016 – Teva Pharmaceutical Industries had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $66.00 price target on the stock.
  • 8/15/2016 – Teva Pharmaceutical Industries had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $80.00 price target on the stock.
  • 8/10/2016 – Teva Pharmaceutical Industries was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $58.99 price target on the stock.
  • 8/8/2016 – Teva Pharmaceutical Industries had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $57.00 price target on the stock, up previously from $55.00.
  • 8/5/2016 – Teva Pharmaceutical Industries had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock, down previously from $75.00.
  • 8/5/2016 – Teva Pharmaceutical Industries was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating. They now have a $70.29 price target on the stock.
  • 8/3/2016 – Teva Pharmaceutical Industries had its “buy” rating reaffirmed by analysts at Jefferies Group.
  • 8/1/2016 – Teva Pharmaceutical Industries was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $60.02 price target on the stock.
  • 8/1/2016 – Teva Pharmaceutical Industries had its “neutral” rating reaffirmed by analysts at Credit Suisse Group AG.
  • 7/26/2016 – Teva Pharmaceutical Industries had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $75.00 price target on the stock.
  • 7/25/2016 – Teva Pharmaceutical Industries had its “buy” rating reaffirmed by analysts at Mizuho.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) opened at 50.36 on Wednesday. The stock has a market capitalization of $46.03 billion, a P/E ratio of 33.64 and a beta of 0.82. The firm’s 50-day moving average price is $52.25 and its 200 day moving average price is $53.29. Teva Pharmaceutical Industries Ltd has a 52 week low of $48.01 and a 52 week high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.05. The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.86 billion. During the same quarter last year, the firm earned $1.43 EPS. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Ltd will post $5.26 earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/teva-pharmaceutical-industries-teva-analysts-weekly-ratings-changes.html

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Monday, August 22nd were given a dividend of $0.34 per share. The ex-dividend date was Thursday, August 18th. This represents a $1.36 annualized dividend and a dividend yield of 2.70%.

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.